Bio-Rad officer proposes $359K stock sale

The shares are identified as restricted stock acquired from the issuer on October 24, 2025.

Available on EDGAR 11/09/2026 - 05:28 PM EST Accepted by SEC EDGAR 11/09/2026 - 05:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BIO-RAD LABORATORIES, INC. officer Jonathan DiVincenzo reported a proposed sale of 919 common shares, with an aggregate market value of $358,841.93 and an approximate sale date of November 9, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares are identified as restricted stock acquired from the issuer on October 24, 2025.

Key Figures

Shares to be sold: 919 common shares Aggregate market value: $358,841.93 Shares outstanding: 21,832,130 shares +1 more

4 metrics

Shares to be sold 919 common shares Proposed sale

Aggregate market value $358,841.93 Shares proposed for sale

Shares outstanding 21,832,130 shares Common shares outstanding listed

Approximate sale date November 9, 2026 Proposed sale

Key Terms

Restricted Stock, Aggregate Market Value

2 terms

Restricted Stock financial

"Nature of Acquisition Transaction: Restricted Stock"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Aggregate Market Value financial

"Aggregate Market Value 358841.93"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BIO shares is Jonathan DiVincenzo proposing to sell?

Jonathan DiVincenzo, an officer of BIO-RAD LABORATORIES, INC., reported a proposed sale of 919 common shares, with an aggregate market value of $358,841.93. The approximate sale date is November 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001453524
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BIO-RAD LABORATORIES, INC.
SEC File Number	001-07928
Address of Issuer	1000 ALFRED NOBEL DRIVE HERCULES CALIFORNIA 94547
Phone	510-724-7000
Name of Person for Whose Account the Securities are To Be Sold	JONATHAN DIVINCENZO
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	919	358841.93	21832130	11/09/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/24/2025	Restricted Stock	Issuer			919	10/24/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jonathan DiVincenzo
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)